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Imaging has become a cornerstone for medical diagnosis and the guidance of
patient management. A new field called image-guided drug delivery (IGDD)
now combines the vast potential of the radiological sciences with the delivery of
treatment and promises to fulfill the vision of personalized medicine. Whether
imaging is used to deliver focused energy to drug-laden particles for enhanced,
local drug release around tumors, or it is invoked in the context of nanoparticle-
based agents to quantify distinctive biomarkers that could risk stratify patients
for improved targeted drug delivery efficiency, the overarching goal of IGDD is
to use imaging to maximize effective therapy in diseased tissues and to minimize
systemic drug exposure in order to reduce toxicities. Over the last several years,
innumerable reports and reviews covering the gamut of IGDD technologies have
been published, but inadequate attention has been directed toward identifying
and addressing the barriers limiting clinical translation. In this consensus opinion,
the opportunities and challenges impacting the clinical realization of IGDD-based
personalized medicine were discussed as a panel and recommendations were
proffered to accelerate the field forward. © 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Over the last several years, the concept of the‘magic therapeutic bullet’ has come much closer
to realization in the lab but these results have been
slow to reach the clinic.1 Individualized targeting
of drugs with the intent of improving safety and
efficacy has evolved along two parallel paths with
biomedical imaging playing a major role. The field
of IGDD, which takes advantage of the strengths
of imaging to optimize drug therapy, has emerged
with promises to fulfill the vision of personalized
medical treatment. Along one path, imaging is used
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to visualize the target lesion and affect the local
release or activation of drugs through image-guided
deposition of exogenous energy. As an example, the
biodistribution of drug may be altered by focused
energy disruption of temperature-sensitive drug-
laden liposomes to preferentially release free drug
at the target.2–6 Another example is image-guided
hyperthermia, where particles bound near or in the
target tissue are heated via light, magnetic, or acoustic
energy to affect cell death.7–16
The other path of IGDD technologies involves
so-called theranostic agents, i.e., a pharmaceutical
with drug delivery and targeted diagnostic imaging
features. Theranostic platform technologies may be
used diagnostically to characterize a patient’s disease
and biomarkers and then for the appropriate subset
of those individuals, the same platform can be
functionalized to deliver treatment.4,6,7,17–84 In some
instances, the agent may engender both imaging
and therapeutic features simultaneously providing
image-based confirmation and quantification of the
delivered drug, so-called rational dosimetry. Image-
based rational dosimetry helps to assure adequacy
of treatment and informs further medical care plan
decisions immediately. It can eliminate undesirable
delays in determining poor outcomes, which result
from underdosing or ineffective treatments. In
each circumstance, molecular imaging can provide
longitudinal information about the biochemical and
microanatomic response to treatments, including the
early recrudescence of the underlying disease.
Regardless of approach, IGDD offers significant
opportunity as a partner in medical management
beyond the traditional diagnostic imaging role.
While reports and reviews covering the gamut
of technologies related to IGDD have touted the
exciting opportunities, this opinion focuses on the
perceived barriers limiting clinical translation of these
achievements. This panel of informed scientists was
assembled by the National Cancer Institute (NCI) to
consider the issues impeding the ‘bench to bedside’
transition of these technologies. Comments as to
the direction of research and development efforts to
address these unique challenges presented are not
necessarily endorsed by the NCI or NIH.
CHALLENGES AND
RECOMMENDATIONS FOR IGDD
Efficacy and Safety Issues Surrounding
IGDD
Challenge: Optimizing drug concentrations delivered
to the target cells mediating the disease.
Opinion: Consistent with a ‘walk before you
run’ perspective, the first generation of nanoparticle
and microparticle technologies now reaching the
clinic is primarily nontargeted or ‘vascularly targeted’
applications, which address diseases such as cancer,
arthritis, atherosclerosis, and macular degeneration.
Most of the nontargeted agents, whether liposomal,
polymeric, emulsions, or micelles, are generally exten-
sions of traditional prolonged release drug delivery
strategies intended to alter the pharmacokinetic
profile of drugs in vivo and to a lesser extent to alter
the biodistribution.
IGDD liposomal- or microbubble-based agents
alter free drug pharmacokinetics and afford increased
localized release when exogenous focused energy,
such as high-intensity focused ultrasound, is applied.
Therefore, locally increased concentrations of free
drug will increase the percentage of the injected dose
delivered. The penetration and target cell uptake of
even small molecules must traverse several barriers
and the rapidity of drug washout in blood from lesion
can diminish the expected benefit. Exogenous energy
can mechanically weaken or destroy the biological
barriers giving improved access to the extravascular
space, but still the issues of free drug cellular
uptake versus washout can detract from the potential
benefit.
From a nanoparticle molecular imaging perspec-
tive, vascular-constrained agents targeted to biomark-
ers expressed differentially by endothelial cells can
aid patient diagnosis, therapeutic risk stratification,
and longitudinal management. However, from a treat-
ment perspective, drug, gene, or biological, vascular-
targeted approaches only impact the endothelium
directly and influence the underlying pathology usu-
ally through secondary effects. Thus, many vascular-
targeted agents may best be used adjunctively to
improve the efficacy of current systemic regimens.85
However, growing evidence suggests that vascular-
targeted agents can be actively transported into lesions
quickly and against the blood to tissue concentration
gradient.
IGDD technologies, whether related to image-
localized release of drug from nontargeted particles or
targeted nanobased molecular imaging and therapy,
will benefit from deeper penetration of particles into
the disease site. Mechanical disruption of drug-laden
particles within lesions using image-guided focused
energy would increase compound bioavailability
to target cells and reduce washout of free
drug. Microbubble systems undergoing intratumoral
disruption would offer further synergistic effect by
improving the biodistribution of free drug and by
sonically impacting target cell permeability.80,86
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Most investigators studying systemically tar-
geted and nontargeted nanoparticles rely on the
purported ‘enhanced permeability and retention’
(EPR),87,88 a phenomenon primarily observed with
subcutaneous xenograft mouse tumors. This effect is
muted in less promiscuous models such as orthotopic
transplants in mice or larger species. Ultimately,
particulate agents larger than modestly sized proteins
are poorly exchanged into vascular periphery of
tumors, arthritic joints, or atherosclerotic plaques
where deep drug penetration is desired.
The natural receptors or ‘door keys’ that
selectively regulate endothelial uptake and trafficking
of blood-borne constituents into the interstitium
are known only to a limited extent.89–121 The
regulatory communication signals emanating from
normal and pathological extravascular cells that
modulate endothelial cellular functions are a mystery
with only fragmentary clues. The concept of targeted
delivery through natural endothelial transcytosis
systems, such as the caveolae system,122–128 has
been demonstrated for smaller agents, such as
antibodies and very small nanoparticles with at
least one caveolae-specific marker, i.e., a modified
aminopeptidase 2 (APP 2). Using a monoclonal
antibody against APP2, the Schnitzer laboratory
has delivered radiolabeled payloads and small gold
nanoparticles (10 nm) into lung parenchyma firmly
demonstrating the principle. For caveolae-exploited
transport mechanisms, antibody transport (pumping)
into the extravascular space can be rapid with up to
70% of the injected dose delivered in a few minutes
against the blood-to-tissue concentration gradient.
Ultimately, these investigators injected increasingly
lower doses to avoid saturating the delivery
mechanism, while maximizing lung parenchymal
delivery. Co-opting caveolae transcytosis mechanisms
for some treatment regimens will accelerate targeted
delivery and reduce total drug dose exposure.
Moreover, utilizing a caveolae transcytosis approach
would obviate the need to pursue avoidance of
the reticuloendothelial system (RES), because the
clearance of untargeted agent can be desirable.
Decreasing the whole-body particle burden would
improve safety profiles, including a reduction in ‘flu-
like’ symptoms associated with cytokines released by
an activated RES.
Caveolae likely serve both constitutive and
specialized transport roles. While the component parts
of the system are defined mechanistically to a great
extent, virtually no specific information concerning
the physiological regulation (internal and external) of
the ‘machine’, the cargo, and the transendothelial
throughput exists in the cell biology literature.
Discovery of organ- or pathology-specific caveolae
markers with supportive characterization is minimal
to date and far from the needed caveolae vascular
map required to propel IGDD development along
this pathway. A better understanding of basic cell
biology specifically delineating the dynamic and
biophysical constraints of caveolae transport using
nanotechnology-based probes is needed.
As mentioned, the transmigration of large cells,
such as macrophages, neutrophils, and lymphocytes,
occurs through the endothelial cell itself, and is
ongoing constantly to mediate inflammation responses
to infection, atherosclerosis, cancer, arthritis, and
more. Several participatory biomarkers involved in
attracting and concentrating these cells along the
apical endothelium lumen from where intercellular
adhesion molecule (ICAM)-mediated transcytosis to
basal and lateral membranes release agents into
the extravascular space.129–133 The importance of
this pathway is highlighted by the development of
small-molecule antagonists of lymphocyte function-
associated antigen, αLβ2 (LFA-1), to prevent LFA-
1/ICAM-mediated leukocyte transcytosis.134–137
The Muro laboratory has conducted enlighten-
ing early studies demonstrating that the ICAM path-
way can be usurped to transcytose 100-nm polystyrene
nanospheres electrostatically coated with anti-ICAM
antibody through Caco-2 epithelial cells (a continu-
ous line of heterogeneous human epithelial colorectal
adenocarcinoma cells) in vitro, providing convinc-
ing data using transmission electron microscopy and
cell transwells. She has extended the characteriza-
tion of endothelial ICAM cell biology biochemical
mechanisms from cells to nanoparticles with detailed
proof of concept studies. Yet, little interest within
the endothelial cell biologist community in the IGDD
problem has been forthcoming. Perhaps, the parti-
cle transcytosis topic is relatively unknown among
those scientists or the issue is not effectively ele-
vated for study by targeted funding opportunities
on the topic. While ICAM is an important ele-
ment for larger particles to enter lesions, it is only
one of what may be many pathways. Other mecha-
nisms exist, such as the iRGD approach (RGD refers
to the recognition amino acid sequence for integrin
binding to many extracellular matrix proteins) prof-
fered by the Ruoslahti laboratory,138–141 and natural
pathways by which lipoproteins, like high-density
lipoprotein, enter the extravascular space of tumors
and plaques.94,142,143 Certainly, more pathways for
communicating from the blood to the extravascular
space and the reverse exist.
Today, much effort continues to be expended
to chemically optimize particles for passive particle
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delivery and entrapment with delayed washout (EPR).
Unfortunately, the penetration via leaky vasculature
has proven to be highly limiting or ineffective in
many situations. For efficient delivery of payloads
into tumors, plaques, or joints, a much greater
understanding of how nature has evolved to achieve
these same goals with extraordinary precision, speed,
and efficiency is needed. In the interim, substantive
clinical therapeutic improvements can be achieved
through image-guided focused energy release of drugs
and vascular-targeted therapies that may be effective
alone or act synergistically as adjuvants with current
medical management regimens.85,144,145
Challenge: Avoiding premature clearance of
therapeutic particles before effective drug delivery is
achieved.
Opinion: Nanoparticles and microparticles are
typically cleared by RES system, which is composed
of phagocytic cells in the lung, spleen, liver, and
marrow. The RES system is currently conceived as a
hindrance to the efficacy of targeted particles, because
the rapid clearance of particles offsets the high
concentration gradient needed as a driving force for
passive transport and delivery. Indeed, the need for
high mass loading and prolonged circulatory times
for EPR to have any impact can only be achieved with
improved RES avoidance.146–148 PEGylation (i.e.,
PEG, polyethylene glycol) of particles has been used
to create ‘stealthy’ agents and slow RES clearance
rates, but it can impair ligand-directed targeting due
to steric interference. Moreover, PEG, once thought
to be a benign surface modifier, because it diminished
complement activation (CA), can induce adaptive
immune responses with repeat usage.149–152
Another approach to the RES issue has been
to make particles very small, even approaching the
size of large proteins. While the lung, liver, and
spleen are all well-known RES constituents acting
in a coordinated sieve-like manner particularly on
larger particles (>20 nm), the marrow is generally
overlooked but is a depot for very small particles.
The marrow has many phagocytic cells, and large
(300 nm) and small particles (20 nm) are found to
collect there. The marrow, which weighs 2.6 kg in
adults (by comparison the liver is 1.5 kg), constantly
maintains and replenishes platelets, leukocytes, and
erythrocytes in addition to its clearance functions,
and it may be functionally sensitive to particle
engorgement. Regardless, the RES clearance in the
marrow will be challenging to overcome.
On the other hand, RES clearance can be
beneficial. The removal of therapeutic particles from
circulation reduces off-target effects, which is typically
reflected as decreased drug toxicity with IGDD
treatments. For imaging, the removal of contrast agent
from the circulation decreases background blood pool
interference and improves contrast-to-noise ratios
for targeted pathologies. The key to RES problem
will likely resolve when faster and more efficient
extravascular targeting of disease is achieved by
utilizing natural cell transport mechanisms, which will
allow much lower drug dosing levels and leave the RES
to clear unneeded drug and prevent off-target effects.
Challenge: Designing particles to avoid CA and
adaptive immune responses.
Opinion: Unlike drugs, which are typically small
molecules, particulate-based technologies can elicit
host blood contact responses, including hemolysis,
CA, or immune response. The relevance of particle
shape, charge, and size is coming to the fore, but
informed de novo design guidance of nanoparticles
and microparticles to avoid these issues is not
available. Nature’s ‘rules’ governing the acute and
adaptive immune responses to particle surfaces remain
poorly delineated and understudied.
Animal immune responses to particle challenges
need to be conducted to define the response with acute
and repeat administration.153 Assay methodology for
CA and adaptive immunity assessments must be devel-
oped to clearly assess clinically relevant signal with
minimal false positives. Clear guidance must be estab-
lished to distinguish results that would elicit low-level,
subclinical responses from those reflecting clinically
meaningful risk that warrants concern and reformula-
tion. An easily available set of nanoparticle standards
and simply executed method kits must be demon-
strated and validated through interlaboratory testing
and standardized through ASTM (American Society
for Testing and Materials) or similar organization.
Importantly, techniques developed must be readily
performed by any laboratory routinely synthesizing
new agents. Public access databases documenting
appropriate physical, chemical, and biological char-
acterization of test particles using these standardized
methods should be established and easily interrogated.
Pooled serum animal or human serum can blunt
individual biological variation estimations. Serum
from asymptomatic people as well as those with
select patients with specific underlying pathologies
should be obtained and developed into standardized
panels to gain insight into the expected variability
of responses. As no exogenous material introduced
into humans will be completely safe, we should
not expect such to be the case for particle-based
technology. A common clinical example of high
benefit with acceptable risk involves microbubble
acoustic diagnostics. CA triggered by microbubbles
can lead to transient (few minutes) episodes of back
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pain or neurological symptoms in echocardiography
laboratory. While this is sometimes momentarily
uncomfortable for the occasional patient, the overall
health risk is very low and outweighed by the vastly
improved diagnostic benefit.154 Appropriate product
labeling and monitoring should be anticipated until a
sufficient clinical experience warrants a revision.
Clinical Validation of Biomarkers and
Quantitative Imaging
Challenge: Biomedical imaging results are reported in
qualitative, relativistic, and descriptive terms. How-
ever, molecular imaging for the purpose of patient
risk stratification and longitudinal management
should be quantitative and repeatable overtime and
across institutions.
Opinion: Too little work has considered how
image contrast signals might be used clinically, partic-
ularly when used diagnostically for rational dosimetry,
patient stratification, or longitudinal medical man-
agement. To utilize molecular imaging or blood pool
signals serially in the same patient to support medical
decisions requires accurate, precise, and repeatable
quantitation rather than the relativistic measures typi-
cally reported in preclinical studies. Robust quantifica-
tion that can be normalized across exams and between
institutions would support the implementation of
guidelines and the development of algorithmic patient
management decision trees. Such IGDD uniformity
will require the creation and distribution of reference
phantoms for instrument and image calibration. To
this end, appropriate quality control procedures and
reference standards could be established and validated
through NIST (National Institute of Standards and
Technology). Importantly, such reference standards
will allow manufacturers of instruments and software
to achieve and report comparable outcome data
while still allowing vendor unique algorithms for
quantification. Ultimately, IGDD quantification must
be easily and reproducibly adopted by imaging
and pharmaceutical laboratories engaging in these
advanced services to patients and physicians.
Challenge: Current models provide limited
understanding of the temporal and spatial variation in
receptor expression relative to the natural progression
of disease, clinical status, and prognosis in humans.
Opinion: Nature reuses the same or closely
related proteins on many cell types for related
purposes. Although homing ligands with high affinity
and specificity are implicitly required, targeted
therapies must also be validated to bind specifically to
the proper subset of cells to avoid misinterpretations
and off-target toxicity. Moreover, given the current
limited understanding of the temporal and spatial
variation in receptor expression in man or its relevance
to the natural progression disease, clinical status, and
prognosis in patients, a serious effort to characterize
the time-course expression of potential pathological
biomarkers in man is essential.
Cost-efficient preclinical models that better
recapitulate human disease need to be established
and broadly available. Today, most preclinical models
only provide modest confidence that a compound
or nanoagent is biologically active in vivo and
only offers gross indications of toxicity. As animal
models must be used to correlate imaging data,
ideally with clinically relevant instrumentation, newer
preclinical models beyond mice are needed. However,
such models require supportive immunohistochemical
and molecular biology reagents, which are generally
lacking. It is clear that imaging and therapeutic
success in mice must be confirmed and augmented
in secondary species to improve the odds of
clinical translation. Perhaps, alternative models such
as the rat, rabbit, guinea pig, hamster, or even
avian species should be explored more aggressively.
Programmatic impetus to further develop these models
with complementary reagents for specific disease
applications would be welcome.
In the nearer term, we should consider new
regulatory pathways to acquire human IGDD data
safely sooner. Perhaps, a more flexible extension to
Phase 0 feasibility testing paradigm at higher doses
applicable to microtechnologies and nanotechnologies
could be envisioned for research studies using Good
Laboratory Practice (GLP)-produced agents that have
completed a reduced essential battery of preclinical
testing. If these agents have only minor issues at low
doses in a few patients, then they could be stepped
into Phase 1 as is or with additional supporting data.
If an unexpected event occurs, it would be known
earlier and transition to Phase 1 would be dependent
on further clarification of that issue and safety impact.
Today, the current development cycle is too long
and too risky for nanomedicines, particularly IGDD
technologies, and this has suppressed innovation
and translation by decreasing financial investment.
Broadly speaking, an accelerated regulatory program
would have a significant positive impact on the
US biotechnology and pharmaceutical industries,
particularly for the myriad small companies dependent
on limited private equity and governmental funding.
Increasing Physician Involvement in
Nanotechnology and IGDD Research
Challenge: In recent years, the development of IGDD
technologies has been driven predominantly by basic
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and applied scientists and engineers who need the
insight into the unmet clinical needs and perspectives
that can be provided by physician scientists.
Opinion: Ultimately, IGDD technologies must
be ‘pulled’ into the clinic by end users inspired
to address previously intractable medical problems.
Many IGDD concepts are developed without
adequate consideration of clinical unmet need for
a specific application. The practical insight of
progressive, technology savvy physicians, radiologists,
and surgeons engaged in IGDD projects, program
advisory boards, and grant review panels would
enlighten other research scientists as well as provide
an increasing pool of informed key to key individuals
that influences physician/scientists to communicate the
opportunities and limitation of these technologies to
their colleagues. A greater effort to address medical
and scientific constituencies beyond our IGDD
colleagues is required, both to create enthusiasm for
developing these new concepts and to preempt adverse
messaging based on myths, conjectures, hyperbole,
and bias. An educated medical community would
be a primary resource to answer the questions of
curious patients and interested parties at all levels of
organization.
Synergizing Academic Communities,
Government, and Private Industrial
Resources
Challenge: The multidisciplinary nature of imaging
and drug delivery research presents expertise-based
barriers from academic discovery through commercial
development.
Opinion: The drug delivery and imaging
communities are historically disjoint as scientific
societies, as funding review panels, and within
educational programs. Significant expertise in medical
pharmacology has developed within the delivery
community in parallel to expertise in physics and
biology within the imaging community. Bridging these
communities remains a challenging problem and the
educational infrastructure required to unite these fields
has not yet been created.
With regard to the divide between academics
and industry, the strength of academia lies in
the formulation of imaginative concepts, the
development of research prototypes, and the pursuit
of rigorous experimentation. Academics lack expertise
in the formal development of complicated drugs
and imaging agents. Pharmaceutical and medical
imaging companies, while clearly not lacking in
creative or scientific potential, must currently focus
on development projects with high potential for
translation to the clinic.
Efforts to conjoin the imaging and delivery
communities are now emerging through combined
scientific sessions and new funding review panels. A
continued effort to create such venues for discussion
and focus will be important. Moreover, educational
programs specifically aimed at creating the next
generation of scientists who are formally trained in
both the imaging and delivery disciplines have not yet
emerged. The fundamental challenge is to incorporate
sufficient training in chemistry, biology, mathematics,
and physics within such a program to guarantee that
trainees master the core competencies of both the
imaging and delivery communities. While molecular
imaging training programs have recently emerged, the
challenges of therapeutic delivery require additional
training materials and expertise.
Further, clinical translation of IGDD research
has always been limited by technical and cultural gaps
between the biology–chemistry-driven pharmaceutical
and physics–engineering-based medical instrumenta-
tion industries. Combination imaging and therapy
product concepts are outside the mainstream exper-
tise of either industry. Although academia continues
to conceive of new IGDD innovations, this community
lacks product development, regulatory, management,
and marketing experience. The translational prospects
of new concepts need to be evaluated through the eyes
of experience practitioners, and too few academics
have adequate industry or regulatory experience to
self-evaluate their own technologies with confidence.
Academic scientists often develop early-stage
technology as an individual or as part of a small start-
up company, but generally such technologies must be
transferred to a company or institution to develop,
market, distribute, and support the new technology in
the medical community. What type of company can
best develop IGDD products, imaging or pharmaceu-
tical companies? Likely the answer is a pharmaceutical
company with an imaging collaborator(s) but the
corollary is reasonable in some circumstances.
With financial resources limited in all sectors of
research and development, programs that encourage
corporations to engage and guide promising IGDD
technology at early development stages while main-
taining a low overall economic risk profile are desired.
Industrial expertise, applied as consultation under a
joint development program, could guide preclinical
decisions into desirable directions compatible with
long-term business plans of a corporate partner.
Being in sync with the business goals of a corporate
partner from the start is highly preferred over seeking
a relationship when the product application is at the
investigational new drug application (IND) stage.
Small start-up companies may be useful to de-risk
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Discovery 
early development 
proof in models 
patent protection
Academic-driven research to establish concept and 
decrease project risk with government 
and/or foundation support
Small company formation with adequate capitalization 
through venture capital or private investment to optimize, 
produce, and develop commercial product through Phase 1 
(optional)
Early industry guidance in product development 
with increasing responsibility for clinical testing, regulatory 
affairs, manufacture, commercialization, and market development
Lenza et al. Wires: Nanomedicine and Nanotechnology. 2013 (in review)
Define use 







Integrated academic-government-private partnership 
will accelerate IGDD technology translation to the clinic
Phase 1a/1b




FIGURE 1 | Potential paradigm for increasing the efficiency of ‘bench to the clinic’ translation of image-guided drug delivery (IGDD) technology
achieved by synergizing the creativity of academia under government or foundation support with the product development and marketing capability
of industry. Small companies capitalized by venture capital or private funds may serve to convert academic technology into pharmaceutically suitable,
commercially scalable technologies that are produced under GLP to conduct preclinical stability and safety and GMP to open an IND for initiating
Phase 1 human clinical trials. Involvement of industry provides smooth transition into later-phase clinical studies and the market. CMC, chemistry,
manufacturing, and controls; IND, investigational new drug application; GLP, Good Laboratory Practices; GMP, Good Manufacturing Practices; NDA,
New Drug Application; CMS, Center for Medicare and Medicaid Services.
new technology between academic discovery and
clinical proof in human stages. In today’s economic
environment, acquiring the capital needed to bridge
this gap is more likely invested when a larger company
has committed to the clinical pathway and accepted
increasing responsibility and control as the product
concept clears Phase 1 and is poised to expand into
Phase 2 and beyond (Figure 1). Such a relationship
allows the interim investors to monetize their interests
within a reasonable time interval for investment and
equally offers the larger corporation a more de-risked
product concept congruent with its long-term business
plan. The challenge to the IGDD community remains
how to provide incentives for these partnerships.
One mechanism may evolve through programmatic
changes in healthcare reimbursement.
Recently, the New York Times published an
article by Pollack reporting on the revolt of oncologists
over the cost of drugs exceeding $100,000/year
(April 25, 2013). While the cost of developing
sophisticated drugs demands high returns to recoup
investment, often only a fraction of patients respond
as expected while many spend the money and
accept the adverse medical event risk without benefit.
Cost-effective pre-evaluation to qualify patients for
these expensive therapeutic regimens should be
required. For many diseases, IGDD approaches offer a
relatively inexpensive, direct study capable of yielding
substantially improved outcomes in patients selected
for treatment. Moreover, IGDD stratification could
help avoid unnecessary exposures to adverse drug
effects and save $100,000/patient for the majority of
cases in which therapeutically benefit is unlikely.
SUMMARY
While the concept of personalized medicine is often
tangentially inferred in many contexts, IGDD is
a direct path to this goal. Treatments can be
individualized through visualizing pathology and
controlling the local delivery of therapy through
focused energy or by stratifying a patient cohort
with imaging to better ensure responsiveness to
treatment. While numerous challenges face all
new technologies, materializing the opportunities
presented by IGDD continues to require addressing the
significant interdisciplinary challenges and biological
barriers. Vascular-targeted delivery of drug and
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imaging agents is feasible today, but penetration into
lesions with particles passively has not succeeded.
New concepts to co-opt natural transport mechanisms
are emerging and some have substantial proof
of concept, but too little detailed understanding
of these biological transcytosis mechanisms with
regard to their triggers, capacities, constraints, and
biological control mechanisms exists. Partnerships
of cell biologists and IGDD researchers should
be encouraged programmatically to discover and
exploit these cellular functionalities. The added
complexity of developing IGDD technologies requires
new approaches to create economic incentives
for partnerships between commercial and the
academic/government communities. Perhaps, the
single biggest incentive may arise for the healthcare
payers insisting that the use of highly expensive
personalized medicines should be predicated upon
effective documentation that a patient has a 60%
or better chance of a successful outcome. For
therapies with low overall benefit in all-comers
treatment approach, imaging-guided technologies
could make the difference by improving effective
drug delivery into the lesion with energy or by
predetermining those patients most likely to respond
treatment.
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